The E2F transcription factor 2: What do we know?


Journal

Bioscience trends
ISSN: 1881-7823
Titre abrégé: Biosci Trends
Pays: Japan
ID NLM: 101502754

Informations de publication

Date de publication:
11 May 2021
Historique:
pubmed: 7 5 2021
medline: 30 11 2021
entrez: 6 5 2021
Statut: ppublish

Résumé

E2F transcription factor 2 (E2F2) is a member of the E2F family of transcription factors. The classical view is that some E2Fs act as "activators" and others "inhibitors" of cell cycle gene expression. However, the so-called "activator" E2F2 is particularly enigmatic, with seemingly contradictory roles in the cell cycle, proliferation, apoptosis, inflammation, and cell migration and invasion. How can we rationalize the apparently opposing functions of E2F2 in different situations? This is difficult because different methods of studying E2F2 have yielded conflicting results, so extrapolating mechanisms from an observed endpoint is challenging. This review will attempt to summarize and clarify these issues. This review focuses on genetic studies that have helped elucidate the biological functions of E2F2 and that have enhanced our understanding of how E2F2 is integrated into pathways controlling the cell cycle, proliferation, apoptosis, inflammation, and cell migration and invasion. This review will also discuss the function of E2F2 in cancer and other diseases. This review provides a strong basis for further research on the biological function and clinical potential of E2F2.

Identifiants

pubmed: 33952804
doi: 10.5582/bst.2021.01072
doi:

Substances chimiques

E2F2 Transcription Factor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-92

Auteurs

Luwen Li (L)

Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University, Ji'nan, China.
Key Lab for Biotech-Drugs of National Health Commission, Ji'nan, China.
Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University, Ji'nan, China.

Shiguan Wang (S)

Medical College, Shandong University, Ji'nan, China.

Yihang Zhang (Y)

Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University, Ji'nan, China.
Key Lab for Biotech-Drugs of National Health Commission, Ji'nan, China.
Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University, Ji'nan, China.

Jihong Pan (J)

Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University, Ji'nan, China.
Key Lab for Biotech-Drugs of National Health Commission, Ji'nan, China.
Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University, Ji'nan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH